Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Brooks Laboratories's Pretax Margin % or its related term are showing as below:
BOM:533543'
s Pretax Margin % Range Over the Past 10 Years
Min: -61.41 Med: -22.16 Max: 28.67
Current: 28.67
BOM:533543's Pretax Margin % is ranked better than 90.84% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:533543: 28.67
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Brooks Laboratories Pretax Margin % Related Terms
Brooks Laboratories Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533543 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brooks Laboratories (BOM:533543) has a Pretax Margin % of 7.54% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Brooks Laboratories and its competitors. According to the industry distribution chart, Brooks Laboratories ranks #88 out of 961 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is Brooks Laboratories' Pretax Margin % too high?
Brooks Laboratories' current Pretax Margin % is 7.54%. The Drug Manufacturers industry median Pretax Margin % is 7.28. Brooks Laboratories' value of 7.54% is 3.6% above this industry median. Based on the distribution chart, Brooks Laboratories ranks #88 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Brooks Laboratories has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #88 out of 961 companies for Pretax Margin %. This places Brooks Laboratories in the top 9% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Brooks Laboratories' value of 7.54% is 3.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current Pretax Margin % of 7.54% is 3.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Pretax Margin % is 7.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.04, compared to a current price of ₹69.36 — trading 41.2% below its estimated fair value. The current Pretax Margin % is 7.54% and 3.6% above the Drug Manufacturers industry median of 7.28. Brooks Laboratories' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Pretax Margin % is 7.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹69.36 is trading 41.2% below its estimated GF Value™ of ₹118.04.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Pretax Margin %: 7.54%
GF Value™: ₹118.04 vs. price of ₹69.36 (41.2% below fair value)
Industry Position: 3.6% above the Drug Manufacturers median (#88 of 961)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
61GF Score
Get the complete analysis for BOM:533543
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
